Key facts
- AbbVie is reportedly close to acquiring Apogee Therapeutics.
- The potential deal is valued at approximately $10.9 billion.
- The acquisition would be an all-cash transaction.
- Apogee Therapeutics is developing an experimental eczema drug called zumilokibart.
- Zumilokibart is seen as a potential competitor to Sanofi's Dupixent.
- The deal would bolster AbbVie's drug pipeline in the immunology sector.
Pharmaceutical giant AbbVie is reportedly in advanced discussions to acquire Apogee Therapeutics in a deal valued at approximately $10.9 billion in cash. This potential acquisition is poised to significantly enhance AbbVie's existing drug pipeline, especially within the immunology sector. The primary asset driving this interest is Apogee's experimental eczema drug, zumilokibart. This therapy is considered a promising candidate that could emerge as a strong competitor to Sanofi's widely used eczema treatment, Dupixent. The move by AbbVie signals a strategic effort to bolster its presence in the immunology market and secure future revenue streams through promising new drug candidates. The acquisition, if finalized, would represent a substantial investment by AbbVie in expanding its portfolio of treatments for inflammatory conditions.